UK strategy of backing several Covid vaccines seems to be paying off
by Sarah Boseley Health editor from Science | The Guardian on (#5GHR6)
Analysis: buying new and existing technologies ensured alternatives if a vaccine failed or had supply issues
The government has said the decision by Johnson & Johnson to delay the supply of its Covid vaccine to Europe, while the US investigates reports of six cases of unusual blood clots in young women who have had the jab, will not derail the UK's vaccination programme.
That reflects well on the decisions taken by the Vaccines Taskforce, originally headed by Kate Bingham.
Continue reading...